Literature DB >> 15749281

Discovery and development of biomarkers of neurological disease.

Travis Dunckley1, Keith D Coon, Dietrich A Stephan.   

Abstract

The identification of clinically relevant biomarkers for neurological diseases poses unique challenges. These include an historical lack of availability of relevant tissues from the site of pathology, relatively poorly matured techniques for disease diagnosis, the complexity and cellular heterogeneity of the brain, and a clear deficiency of models for functional validation of candidate biomarkers. Here, the unique challenges that neurological disorders introduce to biomarker discovery are described and how modern technological advances in genomics, proteomics and metabolomics are overcoming these obstacles and are driving the discovery of novel biomarkers to improve early diagnosis and therapeutic treatment is discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15749281     DOI: 10.1016/S1359-6446(04)03353-7

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  17 in total

Review 1.  The application of NMR-based metabonomics in neurological disorders.

Authors:  Elaine Holmes; Tsz M Tsang; Sarah J Tabrizi
Journal:  NeuroRx       Date:  2006-07

2.  Comprehensive two-dimensional gas chromatography/time-of-flight mass spectrometry peak sorting algorithm.

Authors:  Cheolhwan Oh; Xiaodong Huang; Fred E Regnier; Charles Buck; Xiang Zhang
Journal:  J Chromatogr A       Date:  2007-12-03       Impact factor: 4.759

Review 3.  A generic research paradigm for identification and validation of early molecular diagnostics and new therapeutics in common disorders.

Authors:  Keith D Coon; Travis L Dunckley; Dietrich A Stephan
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

Review 4.  Database resources in metabolomics: an overview.

Authors:  Eden P Go
Journal:  J Neuroimmune Pharmacol       Date:  2009-05-07       Impact factor: 4.147

5.  Metabolic Profiling of Human Blood by High Resolution Ion Mobility Mass Spectrometry (IM-MS).

Authors:  Prabha Dwivedi; Albert J Schultz; Herbert H Hill
Journal:  Int J Mass Spectrom       Date:  2010-12       Impact factor: 1.986

Review 6.  Mass spectrometry-based biomarker discovery: toward a global proteome index of individuality.

Authors:  Adam M Hawkridge; David C Muddiman
Journal:  Annu Rev Anal Chem (Palo Alto Calif)       Date:  2009       Impact factor: 10.745

Review 7.  Turning laboratory findings into therapy: a marathon goal that has to be reached.

Authors:  Beatrix Kotlan; David F Stroncek; Francesco M Marincola
Journal:  Pol Arch Med Wewn       Date:  2009-09

8.  Probing the metabolic aberrations underlying mutant huntingtin toxicity in yeast and assessing their degree of preservation in humans and mice.

Authors:  P Matthew Joyner; Ronni M Matheke; Lindsey M Smith; Robert H Cichewicz
Journal:  J Proteome Res       Date:  2010-01       Impact factor: 4.466

9.  Variability analysis of human plasma and cerebral spinal fluid reveals statistical significance of changes in mass spectrometry-based metabolomics data.

Authors:  Bridgit Crews; William R Wikoff; Gary J Patti; Hin-Koon Woo; Ewa Kalisiak; Johanna Heideker; Gary Siuzdak
Journal:  Anal Chem       Date:  2009-10-15       Impact factor: 6.986

10.  Genomic and Proteomic Biomarker Discovery in Neurological Disease.

Authors:  Rilee H Robeson; Andrew M Siegel; Travis Dunckley
Journal:  Biomark Insights       Date:  2008-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.